PercutaneousCoronaryIntervention

Angioplasty (percutaneous coronary intervention - PCI) This is also sometimes called PTCA - Percutaneous Transluminal Coronary Angioplasty  

Objective To assess the benefits and risks of short term (<12 months) or extended (>12 months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following percutaneous coronary intervention with drug eluting stents.  

Objective To assess the benefits and risks of short term (<12 months) or extended (>12 months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following percutaneous coronary intervention with drug eluting stents.  

In 2013 more than 92 500 percutaneous coronary intervention (PCI) procedures were performed in the United Kingdom alone.1 Bleeding events are among the most common complications; reported incidences vary between 2.2% and 14%.2 Peri-procedural bleeding has a negative effect on patients’ outcomes—as indicated by higher mortality and morbidity and diminished quality of life—and on metrics of healthcare provision such as length of stay and associated costs.3 Large registries of US patients undergoing PCI have shown that 12.1% of in-hospital mortality is attributable to post-procedural bleeding and suggest a significant association between major bleeding and in-hospital mortality across all strata of bleeding risk.4 The 2011 American Heart Association guidelines state that all patients should be evaluated for risk of bleeding before PCI (class of recommendation 1, level of evidence C).5  

Objective To examine whether prospective bleeding risk estimates for patients undergoing percutaneous coronary intervention could improve the use of bleeding avoidance strategies and reduce bleeding.  

Objective To assess the benefits and risks of short term (<12 months) or extended (>12 months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following percutaneous coronary intervention with drug eluting stents.  

Among diabetic patients with severe heart disease, coronary artery bypass grafting (CABG) surgery is better than stenting (percutaneous coronary intervention; PCI) at improving long-term...  

Evidence is mounting for the supplementary benefit over thrombolysis of endovascular therapy in selected patients with acute stroke. Mechanical percutaneous removal of intracerebral clot using an aspiration catheter ensures that the artery is recanalised. Like thrombolysis, the benefits are greater with early treatment, and we need to think about how to achieve this. Evidence on the benefits of rapid primary percutaneous coronary intervention in patients presenting with ST segment elevation myocardial infarction (STEMI) led to a network being set up in the United Kingdom to provide 24 hour care.1 Teams staffing these networks, skilled in opening arteries quickly, could also provide endovascular therapy to selected patients with acute stroke.